Full Press Release Details
to Investigate Alleged Illegal Trading of Public Securities
PA and VANCOUVER, British Columbia, January 23, 2023- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell"
or the "Company"), a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced
today that it has approved measures to address alleged illegal trading activity of its publicly traded securities. The Company believes
that certain individuals and/or companies may have engaged in manipulative and/or suspected illegal trading practices that may have artificially
depressed its share price. As a result, BriaCell is implementing a plan to address this issue which may include legal action.
is working to build one of the leading immuno-oncology companies in the biotech sector with a singular focus on commercializing our novel
immunotherapy approach for cancer patients. While our clinical team remains dedicated to developing these desperately needed therapies,
the Company recognizes that recent milestones have been achieved with the support of loyal investors who are instrumental in the ongoing
development of our assets. By taking action to protect the interests of our shareholders, we are also protecting the interests of the
Company and the tens of thousands of cancer patients in need of effective treatment options. To this end, BriaCell is pursuing avenues
to address alleged illegal activities carried out by various parties potentially working collusively with the intent of depressing the
Company's share price while undermining the interest of our shareholders.
BriaCell Therapeutics Corp.
is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information
is available at https://briacell.com/.
press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate,"
"could," "estimate," "expect," "intend," "seek," "may," "might,"
"plan," "potential," "predict," "project," "target," "aim," "should,"
"will," "would," or the negative of these words or other similar expressions, although not all forward-looking
statements contain these words. Examples of forward-looking statements in this news release include statements that the Company makes
regarding the Company's plans to address alleged illegal activities carried out by various parties potentially working collusively
with the intent of depressing the Company's share price which may include legal action. Forward-looking statements are based on
BriaCell's current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict.
Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and
other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's
most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent
Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities
regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles
on SEDAR at www.sedar.com and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement
are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable
the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange)
accepts responsibility for the adequacy or accuracy of this release.